v3.25.3
Revenue from Contracts with Customers - Summary of Net Sales by Segment and Geographical Area (Details) - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Disclosure of geographical areas [line items]    
Net sales [1] € 19,889 € 18,360 [2],[3]
Biopharma Segment [Member]    
Disclosure of geographical areas [line items]    
Net sales 19,889 18,360 [2],[3]
Biopharma Segment [Member] | Dupixent    
Disclosure of geographical areas [line items]    
Net sales 7,312 6,138 [2]
Biopharma Segment [Member] | Aubagio    
Disclosure of geographical areas [line items]    
Net sales 138 209 [2]
Biopharma Segment [Member] | Industrial Sales [Member]    
Disclosure of geographical areas [line items]    
Net sales 251 274 [2]
Biopharma Segment [Member] | Polio Pertussis Hib Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 1,361 1,348 [2]
Biopharma Segment [Member] | Influenza Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 214 188 [2]
Biopharma Segment [Member] | Nexviazyme    
Disclosure of geographical areas [line items]    
Net sales 387 320 [2]
Biopharma Segment [Member] | Sarclisa    
Disclosure of geographical areas [line items]    
Net sales 276 227 [2]
Biopharma Segment [Member] | Altuviiio    
Disclosure of geographical areas [line items]    
Net sales 542 280 [2]
Biopharma Segment [Member] | Rezurock    
Disclosure of geographical areas [line items]    
Net sales 263 207 [2]
Biopharma Segment [Member] | Cablivi    
Disclosure of geographical areas [line items]    
Net sales 136 113 [2]
Biopharma Segment [Member] | Xenpozyme    
Disclosure of geographical areas [line items]    
Net sales 110 72 [2]
Biopharma Segment [Member] | Tzield    
Disclosure of geographical areas [line items]    
Net sales 29 21 [2]
Biopharma Segment [Member] | RSV Vaccines    
Disclosure of geographical areas [line items]    
Net sales 356 200 [2]
Biopharma Segment [Member] | Meningitis Travel And Endemic Vaccines    
Disclosure of geographical areas [line items]    
Net sales 609 583 [2]
Europe    
Disclosure of geographical areas [line items]    
Net sales 4,144 4,072 [3]
Europe | Biopharma Segment [Member]    
Disclosure of geographical areas [line items]    
Net sales 4,144 4,072
Europe | Biopharma Segment [Member] | Dupixent    
Disclosure of geographical areas [line items]    
Net sales 944 770
Europe | Biopharma Segment [Member] | Aubagio    
Disclosure of geographical areas [line items]    
Net sales 40 95
Europe | Biopharma Segment [Member] | Industrial Sales [Member]    
Disclosure of geographical areas [line items]    
Net sales 241 273
Europe | Biopharma Segment [Member] | Polio Pertussis Hib Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 223 248
Europe | Biopharma Segment [Member] | Influenza Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 52 30
Europe | Biopharma Segment [Member] | Nexviazyme    
Disclosure of geographical areas [line items]    
Net sales 132 95
Europe | Biopharma Segment [Member] | Sarclisa    
Disclosure of geographical areas [line items]    
Net sales 83 64
Europe | Biopharma Segment [Member] | Altuviiio    
Disclosure of geographical areas [line items]    
Net sales 0 0
Europe | Biopharma Segment [Member] | Rezurock    
Disclosure of geographical areas [line items]    
Net sales 23 12
Europe | Biopharma Segment [Member] | Cablivi    
Disclosure of geographical areas [line items]    
Net sales 55 43
Europe | Biopharma Segment [Member] | Xenpozyme    
Disclosure of geographical areas [line items]    
Net sales 44 24
Europe | Biopharma Segment [Member] | Tzield    
Disclosure of geographical areas [line items]    
Net sales 1 1
Europe | Biopharma Segment [Member] | RSV Vaccines    
Disclosure of geographical areas [line items]    
Net sales 85 7
Europe | Biopharma Segment [Member] | Meningitis Travel And Endemic Vaccines    
Disclosure of geographical areas [line items]    
Net sales 96 97
UNITED STATES    
Disclosure of geographical areas [line items]    
Net sales 9,535 8,292 [3]
UNITED STATES | Biopharma Segment [Member]    
Disclosure of geographical areas [line items]    
Net sales 9,535 8,292
UNITED STATES | Biopharma Segment [Member] | Dupixent    
Disclosure of geographical areas [line items]    
Net sales 5,283 4,437
UNITED STATES | Biopharma Segment [Member] | Aubagio    
Disclosure of geographical areas [line items]    
Net sales 76 96
UNITED STATES | Biopharma Segment [Member] | Industrial Sales [Member]    
Disclosure of geographical areas [line items]    
Net sales 1 1
UNITED STATES | Biopharma Segment [Member] | Polio Pertussis Hib Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 320 311
UNITED STATES | Biopharma Segment [Member] | Influenza Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 54 16
UNITED STATES | Biopharma Segment [Member] | Nexviazyme    
Disclosure of geographical areas [line items]    
Net sales 195 174
UNITED STATES | Biopharma Segment [Member] | Sarclisa    
Disclosure of geographical areas [line items]    
Net sales 119 100
UNITED STATES | Biopharma Segment [Member] | Altuviiio    
Disclosure of geographical areas [line items]    
Net sales 456 259
UNITED STATES | Biopharma Segment [Member] | Rezurock    
Disclosure of geographical areas [line items]    
Net sales 220 188
UNITED STATES | Biopharma Segment [Member] | Cablivi    
Disclosure of geographical areas [line items]    
Net sales 71 60
UNITED STATES | Biopharma Segment [Member] | Xenpozyme    
Disclosure of geographical areas [line items]    
Net sales 47 37
UNITED STATES | Biopharma Segment [Member] | Tzield    
Disclosure of geographical areas [line items]    
Net sales 27 20
UNITED STATES | Biopharma Segment [Member] | RSV Vaccines    
Disclosure of geographical areas [line items]    
Net sales 68 116
UNITED STATES | Biopharma Segment [Member] | Meningitis Travel And Endemic Vaccines    
Disclosure of geographical areas [line items]    
Net sales 319 301
Other Countries    
Disclosure of geographical areas [line items]    
Net sales 6,210 5,996
Other Countries | Biopharma Segment [Member]    
Disclosure of geographical areas [line items]    
Net sales 6,210 5,996
Other Countries | Biopharma Segment [Member] | Dupixent    
Disclosure of geographical areas [line items]    
Net sales 1,085 931
Other Countries | Biopharma Segment [Member] | Aubagio    
Disclosure of geographical areas [line items]    
Net sales 22 18
Other Countries | Biopharma Segment [Member] | Industrial Sales [Member]    
Disclosure of geographical areas [line items]    
Net sales 9 0
Other Countries | Biopharma Segment [Member] | Polio Pertussis Hib Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 818 789
Other Countries | Biopharma Segment [Member] | Influenza Vaccines [Member]    
Disclosure of geographical areas [line items]    
Net sales 108 142
Other Countries | Biopharma Segment [Member] | Nexviazyme    
Disclosure of geographical areas [line items]    
Net sales 60 51
Other Countries | Biopharma Segment [Member] | Sarclisa    
Disclosure of geographical areas [line items]    
Net sales 74 63
Other Countries | Biopharma Segment [Member] | Altuviiio    
Disclosure of geographical areas [line items]    
Net sales 86 21
Other Countries | Biopharma Segment [Member] | Rezurock    
Disclosure of geographical areas [line items]    
Net sales 20 7
Other Countries | Biopharma Segment [Member] | Cablivi    
Disclosure of geographical areas [line items]    
Net sales 10 10
Other Countries | Biopharma Segment [Member] | Xenpozyme    
Disclosure of geographical areas [line items]    
Net sales 19 11
Other Countries | Biopharma Segment [Member] | Tzield    
Disclosure of geographical areas [line items]    
Net sales 1 0
Other Countries | Biopharma Segment [Member] | RSV Vaccines    
Disclosure of geographical areas [line items]    
Net sales 203 77
Other Countries | Biopharma Segment [Member] | Meningitis Travel And Endemic Vaccines    
Disclosure of geographical areas [line items]    
Net sales € 194 € 185
[1] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[2] Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.